Generex and Elan in jv deal
Generex Biotechnology is entering into a joint venture with Elan to pursue the application of their drug delivery technologies got the treatment of prostate cancer, endometriosis and the suppression of testosterone and oestrogen. Elan is also to make an initial US$5m equity investment in Generex. The jv will have non-exclusive licence to use Generex's buccal delivery, and some of Elan's techniques.